CNTB — Connect Biopharma Holdings Balance Sheet
0.000.00%
- $96.40m
- $24.63m
- $26.03m
- 23
- 18
- 95
- 41
Annual balance sheet for Connect Biopharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 20-F | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 157 | 268 | 152 | 118 | 93.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | 0.351 | 1.05 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 162 | 275 | 156 | 123 | 97 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.21 | 12.9 | 8.47 | 4.74 | 4.24 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 166 | 291 | 174 | 127 | 101 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.82 | 18 | 15.6 | 25.3 | 8.46 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 323 | 18.8 | 16.5 | 25.9 | 9.12 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -157 | 272 | 157 | 101 | 92.2 |
| Total Liabilities & Shareholders' Equity | 166 | 291 | 174 | 127 | 101 |
| Total Common Shares Outstanding |